Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 693

1.

Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.

Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M.

Ann Intern Med. 2008 Mar 4;148(5):379-97. Review.

PMID:
18316756
2.
3.

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, Adelman A, Mehr D, Schellhase K, Campos-Outcalt D, Santaguida P, Owens DK; American College of Physicians/American Academy of Family Physicians Panel on Dementia..

Ann Intern Med. 2008 Mar 4;148(5):370-8.

PMID:
18316755
4.

Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.

Clegg A, Bryant J, Nicholson T, McIntyre L, De Broe S, Gerard K, Waugh N.

Int J Technol Assess Health Care. 2002 Summer;18(3):497-507. Review.

PMID:
12391943
5.

A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.

Takeda A, Loveman E, Clegg A, Kirby J, Picot J, Payne E, Green C.

Int J Geriatr Psychiatry. 2006 Jan;21(1):17-28. Review.

PMID:
16323253
7.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

8.
9.

Effective pharmacological management of Alzheimer's disease.

Atri A.

Am J Manag Care. 2011 Nov;17 Suppl 13:S346-55. Review.

10.

Drug therapy of dementia in elderly patients. A review.

Olsen CE, Poulsen HD, Lublin HK.

Nord J Psychiatry. 2005;59(2):71-7. Review.

PMID:
16195103
11.

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.

Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.

J Alzheimers Dis. 2013;35(2):349-61. doi: 10.3233/JAD-122140. Review.

PMID:
23411693
12.

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.

Hartmann S, Möbius HJ.

Int Clin Psychopharmacol. 2003 Mar;18(2):81-5.

PMID:
12598818
13.

Current and emerging pharmacological treatment options for dementia.

Ringman JM, Cummings JL.

Behav Neurol. 2006;17(1):5-16. Review.

PMID:
16720956
14.

[Medical treatment of Alzheimer's disease].

Johannsen P.

Ugeskr Laeger. 2006 Oct 2;168(40):3424-9. Review. Danish.

PMID:
17032609
15.
16.

Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia.

Wong CL, Bansback N, Lee PE, Anis AH.

Can J Neurol Sci. 2009 Nov;36(6):735-9.

PMID:
19960752
17.

[Pharmacotherapy for Alzheimer's disease].

Verhey FR.

Tijdschr Psychiatr. 2006;48(1):17-26. Review. Dutch.

18.

AAFP and ACP release guideline on dementia treatment.

Graham L.

Am Fam Physician. 2008 Apr 15;77(8):1173-5. No abstract available.

19.

Drugs for cognitive loss and dementia.

[No authors listed]

Treat Guidel Med Lett. 2013 Oct;11(134):95-100; quiz 1 p following p100.. Review.

PMID:
24081314
20.

Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.

Van Dam D, Abramowski D, Staufenbiel M, De Deyn PP.

Psychopharmacology (Berl). 2005 Jun;180(1):177-90. Epub 2005 Jan 15.

PMID:
15654502

Supplemental Content

Support Center